6
项与 Autologous CD19-targeting CAR T cells(Hebei Senlangbio Biotechnology) 相关的临床试验The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
To Observe the Long-term Efficacy and Safety of Dual-target Chimeric Antigen Receptor T Cells in the Treatment of Refractory Relapsed B Cell Hematologic Tumors
To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).
An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Non-hodgkin's lymphoma. A total of 100 patients are planned to be enrolled over a period of 3 years.
100 项与 Autologous CD19-targeting CAR T cells(Hebei Senlangbio Biotechnology) 相关的临床结果
100 项与 Autologous CD19-targeting CAR T cells(Hebei Senlangbio Biotechnology) 相关的转化医学
100 项与 Autologous CD19-targeting CAR T cells(Hebei Senlangbio Biotechnology) 相关的专利(医药)
100 项与 Autologous CD19-targeting CAR T cells(Hebei Senlangbio Biotechnology) 相关的药物交易